JP6914860B2 - カチオン性粘液酸ポリマー系デリバリーシステム - Google Patents

カチオン性粘液酸ポリマー系デリバリーシステム Download PDF

Info

Publication number
JP6914860B2
JP6914860B2 JP2017566754A JP2017566754A JP6914860B2 JP 6914860 B2 JP6914860 B2 JP 6914860B2 JP 2017566754 A JP2017566754 A JP 2017566754A JP 2017566754 A JP2017566754 A JP 2017566754A JP 6914860 B2 JP6914860 B2 JP 6914860B2
Authority
JP
Japan
Prior art keywords
polymer
cmap
nanoparticles
alkyl
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017566754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525462A5 (https=
JP2018525462A (ja
Inventor
イー デイビス マーク
イー デイビス マーク
パン ドロシー
パン ドロシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Publication of JP2018525462A publication Critical patent/JP2018525462A/ja
Publication of JP2018525462A5 publication Critical patent/JP2018525462A5/ja
Priority to JP2021116707A priority Critical patent/JP7150945B2/ja
Application granted granted Critical
Publication of JP6914860B2 publication Critical patent/JP6914860B2/ja
Priority to JP2022154411A priority patent/JP7708728B2/ja
Priority to JP2025038440A priority patent/JP2025100542A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/08—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing boron
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyethers (AREA)
JP2017566754A 2015-07-01 2016-06-13 カチオン性粘液酸ポリマー系デリバリーシステム Active JP6914860B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021116707A JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム
JP2022154411A JP7708728B2 (ja) 2015-07-01 2022-09-28 カチオン性粘液酸ポリマー系デリバリーシステム
JP2025038440A JP2025100542A (ja) 2015-07-01 2025-03-11 カチオン性粘液酸ポリマー系デリバリーシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187366P 2015-07-01 2015-07-01
US62/187,366 2015-07-01
PCT/US2016/037166 WO2017003668A1 (en) 2015-07-01 2016-06-13 Cationic mucic acid polymer-based delivery systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116707A Division JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム

Publications (3)

Publication Number Publication Date
JP2018525462A JP2018525462A (ja) 2018-09-06
JP2018525462A5 JP2018525462A5 (https=) 2019-06-13
JP6914860B2 true JP6914860B2 (ja) 2021-08-04

Family

ID=57609004

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017566754A Active JP6914860B2 (ja) 2015-07-01 2016-06-13 カチオン性粘液酸ポリマー系デリバリーシステム
JP2021116707A Active JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム
JP2022154411A Active JP7708728B2 (ja) 2015-07-01 2022-09-28 カチオン性粘液酸ポリマー系デリバリーシステム
JP2025038440A Pending JP2025100542A (ja) 2015-07-01 2025-03-11 カチオン性粘液酸ポリマー系デリバリーシステム

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021116707A Active JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム
JP2022154411A Active JP7708728B2 (ja) 2015-07-01 2022-09-28 カチオン性粘液酸ポリマー系デリバリーシステム
JP2025038440A Pending JP2025100542A (ja) 2015-07-01 2025-03-11 カチオン性粘液酸ポリマー系デリバリーシステム

Country Status (6)

Country Link
US (4) US10287401B2 (https=)
EP (2) EP3317323B1 (https=)
JP (4) JP6914860B2 (https=)
CN (2) CN107922609B (https=)
ES (2) ES2882255T3 (https=)
WO (1) WO2017003668A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
WO2019241327A1 (en) * 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
WO2020241819A1 (ja) * 2019-05-29 2020-12-03 国立大学法人東京工業大学 複合体、医薬、癌治療剤、キット及び結合体
CN119638713A (zh) 2019-12-04 2025-03-18 艾达奈特公司 合成治疗性纳米颗粒的方法和组合物
JP7343874B2 (ja) * 2019-12-26 2023-09-13 株式会社島津製作所 データ処理方法及びデータ処理装置
AU2024246833A1 (en) 2023-03-31 2025-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5693631A (en) 1995-05-30 1997-12-02 Buckman Laboratories International, Inc. Potentiation of the microbicide 2-(thiocyanomethylthio) benzothiazole using an N-alkyl heterocyclic compound
US6034081A (en) 1995-05-30 2000-03-07 Buckman Laboratories International Inc Potentiation of biocide activity using an N-alkyl heterocyclic compound
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5596878A (en) 1995-06-26 1997-01-28 Thermo King Corporation Methods and apparatus for operating a refrigeration unit
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
FR2749853B1 (fr) 1996-06-12 1998-10-16 Rhone Poulenc Chimie Formulation amelioree a base d'un compose hydroxyle et d'un compose amphiphile complexant utilisable notamment pour modifier les proprietes rheologiques d'emulsions
JP2000514440A (ja) 1996-07-09 2000-10-31 ザ ジョーンズ ホプキンス ユニバーシティー 遺伝子輸送システム
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
ES2210808T3 (es) 1997-08-27 2004-07-01 California Institute Of Technology Composiciones y su uso para prevenir la formacion de adherencias en un tejido biologico.
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
WO2000010007A2 (en) 1998-08-17 2000-02-24 California Institute Of Technology Devices and methods for analysis of non-ionic solutes
US6350527B1 (en) 1998-08-27 2002-02-26 Eidgenossische Technische Hochschule Zurich Gels and multilayer surface structures from boronic acid containing polymers
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
PE20011178A1 (es) 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
EP1292591B1 (en) 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
AU2001273071B2 (en) 2000-06-30 2005-09-08 Glaxo Group Limited Quinazoline ditosylate salt compounds
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
IL160010A0 (en) 2001-07-23 2004-06-20 Univ Ramot Methods and compositions for treating fungal infections
US6737504B2 (en) 2001-07-30 2004-05-18 California Institute Of Technology Synthesis of substituted poly(aniline)s
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
EP1439178A4 (en) 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
AP2004003058A0 (en) 2001-12-12 2004-06-30 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth.
PL370858A1 (en) 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
AU2002357193A1 (en) 2001-12-19 2003-07-09 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
AU2003291567A1 (en) 2002-11-19 2004-06-15 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
EP1575562B1 (en) 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Buoyant polymer particles delivering therapeutic agents
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
JP2005119255A (ja) 2003-10-17 2005-05-12 San Quest:Kk 携帯電話画像取り込み機能付き名刺印刷装置
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
WO2005119255A2 (en) 2004-05-12 2005-12-15 Applera Corporation Constrained cis-diol-borate bioconjugation system
EP1773900A4 (en) 2004-07-30 2007-08-29 Basf Ag POLYMERIC BORONIC ACID DERIVATIVES AND USE IN THE MANUFACTURE OF PAPER
US7413173B2 (en) 2004-09-10 2008-08-19 Ric Investments, Llc Molded water chamber base plate for use in a humidifier and ventilator assembly
JP4988578B2 (ja) 2004-10-12 2012-08-01 ルミネックス コーポレーション ミクロスフェアの表面特性を変化させるための方法
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
EP1945240B1 (en) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
US20080267876A1 (en) 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
US7988988B2 (en) 2005-11-21 2011-08-02 Bausch & Lomb Incorporated Contact lenses with mucin affinity
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE
CN101500546A (zh) 2006-08-17 2009-08-05 诺瓦提斯公司 纳米粒组合物
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2009036022A1 (en) 2007-09-10 2009-03-19 Board Of Regents, The University Of Texas System Enhancement of polysaccharide-mediated nucleic acid delivery
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
US20100029545A1 (en) 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery
US8557292B2 (en) 2008-08-13 2013-10-15 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
US8367166B2 (en) 2008-10-31 2013-02-05 Chevron U.S.A. Inc. Synthesis of higher diamondoids
US20120156138A1 (en) 2009-04-14 2012-06-21 Smith Larry J Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
FR2946476B1 (fr) 2009-06-05 2014-03-21 Aeg Power Solutions Bv Convertisseur continu-continu a regulation double alternance
US20100330686A1 (en) 2009-06-29 2010-12-30 Seung Bum Park Nanosensor for sugar detection
CN102906127A (zh) 2009-11-06 2013-01-30 华盛顿大学商业中心 来自两性离子聚合物的自组装颗粒以及相关的方法
US9138418B2 (en) 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
US20120309691A1 (en) 2010-02-04 2012-12-06 Dapeng Zhou Tumor targeted delivery of immunomodulators by nanopolymers
US20130157926A1 (en) 2010-06-18 2013-06-20 Johannes Franciscus Joseph Engbersen Boronated polymers
WO2012024526A2 (en) 2010-08-20 2012-02-23 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
EP2648756A4 (en) 2010-12-10 2016-06-08 California Inst Of Techn ATTAINING THE MESANGIUM WITH NANOPARTICLES OF DEFINED DIAMETER
US10106650B2 (en) 2011-05-13 2018-10-23 The Regents Of The University Of California Reversibly crosslinked micelle systems
DE102012017025B4 (de) 2012-08-28 2018-05-30 Kennametal Inc. Werkzeughalter für einen Schneideinsatz und Baugruppe mit einem solchen Werkzeughalter
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2961395B1 (en) 2013-03-01 2024-06-19 California Institute Of Technology Targeted nanoparticles
ES2737800T3 (es) * 2013-03-01 2020-01-16 California Inst Of Techn Nanopartículas estabilizadas con composiciones de ácido nitrofenilborónico
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
WO2014185964A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos

Also Published As

Publication number Publication date
WO2017003668A1 (en) 2017-01-05
US20210261739A1 (en) 2021-08-26
JP2025100542A (ja) 2025-07-03
US20190202995A1 (en) 2019-07-04
US11041050B2 (en) 2021-06-22
EP3317323B1 (en) 2021-05-26
US10717825B2 (en) 2020-07-21
JP7708728B2 (ja) 2025-07-15
US20200283582A1 (en) 2020-09-10
JP2021181568A (ja) 2021-11-25
US10287401B2 (en) 2019-05-14
CN107922609B (zh) 2020-04-24
CN111643479B (zh) 2023-10-27
CN111643479A (zh) 2020-09-11
ES2980216T3 (es) 2024-09-30
EP3795609B1 (en) 2024-04-03
JP7150945B2 (ja) 2022-10-11
EP3795609A1 (en) 2021-03-24
JP2018525462A (ja) 2018-09-06
ES2882255T3 (es) 2021-12-01
JP2022191285A (ja) 2022-12-27
EP3317323A4 (en) 2019-05-29
CN107922609A (zh) 2018-04-17
EP3317323A1 (en) 2018-05-09
US20170002151A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
JP7150945B2 (ja) カチオン性粘液酸ポリマー系デリバリーシステム
JP5848127B2 (ja) 担体ナノ粒子ならびに関連する組成物、方法およびシステム
Sill et al. Synthesis and characterization of micelle-forming PEG-poly (amino acid) copolymers with iron-hydroxamate cross-linkable blocks for encapsulation and release of hydrophobic drugs
JP6251294B2 (ja) 標的化ナノ粒子
CN105189614A (zh) 用硝基苯硼酸组合物稳定的纳米粒子
TW201008582A (en) Docetaxel polymer derivative, method for producing same and use of same
AU2007350282A1 (en) Dendrimers and methods of making and using thereof
Liu et al. Self-assembling doxorubicin-prodrug nanoparticles as siRNA drug delivery system for cancer treatment: in vitro and in vivo
Pan et al. Cationic mucic acid polymer-based siRNA delivery systems
JP2018070626A (ja) 標的化ナノ粒子
WO2023149528A1 (ja) 新規ブロックコポリマーを含む高分子ミセル
JP7525981B2 (ja) ニトロフェニルボロン酸組成物によって安定化したナノ粒子
JP2019108371A (ja) 標的化ナノ粒子
Chen Advancing Oligonucleotide Therapeutics: Novel Delivery Strategies Explored Through Polymer Conjugates
Pan Development of a Cationic Mucic Acid Polymer-Based Nanoparticle siRNA Delivery System

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210714

R150 Certificate of patent or registration of utility model

Ref document number: 6914860

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250